Lexicon Pharmaceuticals
LXRX
125 hedge funds and large institutions have $299M invested in Lexicon Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 28 increasing their positions, 41 reducing their positions, and 17 closing their positions.
292% more call options, than puts
Call options by funds: $1.13M | Put options by funds: $289K
35% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 17
2% more funds holding
Funds holding: 123 → 125 (+2)
1.46% more ownership
Funds ownership: 70.21% → 71.66% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less capital invested
Capital invested by funds: $344M → $299M (-$44.9M)
32% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 41
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$3.65M |
| 2 |
Jane Street
New York
|
+$1.74M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$1.73M |
| 4 |
Millennium Management
New York
|
+$1.36M |
| 5 |
Goldman Sachs
New York
|
+$1.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.27M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.16M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.12M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$983K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$935K |
LXRX Hedge Fund Activity: Q4 2025 in Review
125 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q4 2025, worth a combined $299M — down 13% from $344M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new LXRX positions and 17 closed out — a net gain of 6 holders — while 28 added to existing stakes and 41 trimmed.
The largest buyer was UBS Group, adding an estimated $3.65M. The largest seller was Citadel Advisors, cutting an estimated $1.27M.
- 125 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q4 2025, up from 123 in Q3 2025.
- Funds reported $299M of Lexicon Pharmaceuticals stock for Q4 2025, down 13% quarter-over-quarter.
- 23 funds opened new Lexicon Pharmaceuticals positions in Q4 2025 and 17 closed out, a net change of +6 holders.
- The largest Lexicon Pharmaceuticals buyer in Q4 2025 was UBS Group, an estimated $3.65M added.
- The largest Lexicon Pharmaceuticals seller in Q4 2025 was Citadel Advisors, an estimated $1.27M sold.
Based on aggregated 13F filings for Q4 2025.